NTLA (Intellia Therapeutics) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 24, 2026)


NTLA Intellia Therapeutics Inc NTLA
70 GF Score
Price $15.43
GF Value $20.67
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Intellia Therapeutics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Intellia Therapeutics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

NTLA vs AUPH, OCUL, VRDN: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Intellia Therapeutics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intellia Therapeutics Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Margin of Safety % (DCF FCF Based) falls into.


NTLA
70GF Score
Intellia Therapeutics Inc NTLA
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Intellia Therapeutics (NTLA) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $15.43 is trading 25.4% below its estimated GF Value™ of $20.67. GuruFocus considers Intellia Therapeutics to be Modestly Undervalued.

Key valuation signals for NTLA:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: $20.67 vs. price of $15.43 (25.4% below fair value)
  • GF Score™: 70/100 with 3 warning signs

No single metric tells the full story. See the NTLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intellia Therapeutics Business Description

Other Exchanges 0JBU:UK38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
70GF Score

Get the complete analysis for NTLA

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.43
Price
$20.67
GF Value